Point of Care or rapid Diagnostics
Point-of-care (POC) and rapid diagnostics deliver near-patient molecular, antigen, serologic and biochemical results in minutes to hours using portable platforms. In military medicine these tests must be ruggedized, simple to use, require minimal sample processing, provide connectivity for surveillance, and support immediate clinical and operational decisions in austere, delayed-evacuation settings.
Technical Challenges
Sample complexity and contamination risk in field conditions (blood, wound exudate, debris).
Maintaining sensitivity and specificity vs. lab reference tests under rapid, simplified assays.
Device ruggedization, battery life, environmental tolerance (temperature, dust, shock).
Connectivity, data security, and seamless integration with force health surveillance systems.
Emerging Opportunities
Rapid, multiplexed assays for polymicrobial wound infections, AMR markers, and coagulopathy.
Minimal-prep, extraction-free molecular tests validated for austere sample types.
Compact, autonomous platforms for prolonged field care with long reagent shelf-life.
Standardized validation pathways and operational performance data in military populations.
Current and Emerging Technologies in Point of Care or rapid Diagnostics
Isothermal molecular amplification (LAMP, RPA)
Rapid, low-power nucleic acid amplification that eliminates thermal cycling; suitable for portable devices detecting pathogens and biodefense agents with short time-to-result.
Rapid PCR and cartridge-based molecular platforms
Fully integrated, closed-cartridge systems delivering lab-grade sensitivity for bacteria, viruses, and AMR genes at the point of care with simplified workflow.
Lateral flow and rapid antigen tests
Low-cost, single-use assays for quick triage and outbreak control; advances include quantitative readers and improved sensitivity via enhanced reagents.
CRISPR-based diagnostics and molecular biosensors
High-specificity molecular detection leveraging CRISPR collateral cleavage or novel biosensing chemistry for rapid, programmable assays against emerging threats.
Microfluidic lab-on-chip and sample-to-answer systems
Integrated fluidics enabling multiplexed testing, small reagent volumes, and automated sample handling ideal for constrained environments and prolonged care.
Wearables and continuous biosensors
Continuous physiologic and chemical monitoring (biomarkers, infection signatures) to detect early deterioration, support remote triage, and augment readiness surveillance.
Portable imaging and POCUS integration
Handheld ultrasound and AI-assisted imaging augment POC diagnostics for trauma, chest injury, and vascular access in forward settings.
Digital readers, AI interpretation, and secure connectivity
Smartphone or dedicated readers standardize results, apply algorithmic interpretation, and transmit encrypted data for force health monitoring and clinical decision support.
Importance to Military Medicine
Immediate battlefield triage and treatment decisions
Rapid diagnostics shorten time-to-intervention for hemorrhage, infection, and respiratory compromise, improving survival in polytrauma and blast injuries.
Prolonged and delayed evacuation management
Enables monitoring and therapeutic decision-making during prolonged field care when laboratory support is unavailable or evacuation is delayed.
Force health protection and outbreak response
Early detection of infectious threats preserves readiness, guides isolation, and informs vaccination and prophylaxis strategies in deployed forces.
Operational resilience in austere environments
Rugged POC systems reduce logistic burdens and enable distributed care across forward and resource-constrained settings.
Alignment with the MTEC Mission
Accelerates translation of military-relevant diagnostics into operations and civilian use, matching MTEC’s mission to move technologies rapidly from concept to fielded solutions.
Supports interdisciplinary collaboration across academia, industry, and DoD to validate ruggedization, clinical performance, and operational utility.
Enables dual-use outcomes that benefit civilian outbreak response, emergency medicine, and remote healthcare while prioritizing warfighter needs.
Aligns with MTEC priorities for prolonged and distributed care, infectious disease detection, and trauma-resilient technologies.
Dual-Use (Military + Civilian) Applications
Civilian surge capacity and emergency rooms: POC devices shorten ED throughput and enhance triage during pandemics and disasters.
Public health surveillance: connected POC tests feed real-time data into outbreak detection and antimicrobial resistance monitoring systems.
Commercial scale-up: dual-use demand drives manufacturing maturity, cost reduction, and regulatory pathways benefiting both military and civilian markets.
Remote and rural healthcare: technologies developed for deployments translate to clinics with limited lab access worldwide.
Explore MTEC Members with Point of Care or rapid Diagnostics Capabilities
MTEC members bring cross-sector expertise—biotech, device engineering, clinical validation, and DoD operational testing—to de-risk and accelerate POC diagnostic solutions.
Consortium resources support iterative field evaluations, access to military clinical sites for operational validation, and pathways to scale for dual-use deployment.
Explore MTEC member profiles to identify partners with assay chemistry, microfluidics, ruggedized hardware, connectivity platforms, and clinical trial capabilities.
150 Members with Point of Care or rapid Diagnostics capabilities.
The University of Texas System is a leading public university system in the United States, dedicated to improving lives through education, health care, and research. With over 256,000 students enrolled across 14 institutions, the UT System is committed to providing affordable access to higher education and producing a skilled workforce to drive Texas's economy.
IQVIA is a global leader in advanced analytics, technology solutions, and clinical research services for the life sciences industry. With a mission to accelerate innovation for a healthier world and a vision to power smarter healthcare for everyone, everywhere, IQVIA leverages unparalleled data, transformative technology, and deep healthcare expertise to drive better patient outcomes. Operating in over 100 countries with approximately 88,000 employees, IQVIA supports pharmaceutical, biotech, medtech, public health, and government organizations with a comprehensive portfolio of services and solutions. The company is recognized for its Connected Intelligence™, healthcare-grade AI, and commitment to sustainability, innovation, and evidence-based insights that shape the future of healthcare globally. IQVIA is also dedicated to reducing health inequities and driving sustainable change through innovation, collaboration, and data-driven solutions, partnering with organizations worldwide to address complex healthcare challenges.
Georgia Southern University is a vibrant institution with over 26,100 students across three campuses in Statesboro, Savannah, and Hinesville. The university offers 132 degree programs at the associate, bachelor’s, master’s, and doctorate levels, emphasizing student success, community impact, and research excellence. With a commitment to inclusivity and engagement, Georgia Southern fosters a supportive environment for diverse learners, including military-affiliated and adult students. The university is dedicated to transforming lives through education and community engagement, aligning its programs with regional needs. Additionally, Georgia Southern provides accelerated pathways for students to fast-track their master's degrees, enhancing educational opportunities. The university also emphasizes career readiness and public impact research, preparing students for successful careers and contributing to community development.
Volatylix, a Cambridge, MA based startup, is dedicated to early diagnosis enabling timely and appropriate treatment benefiting the patient, physician, provider and payor. Our patent pending platform – DECIPHER – and unique detection sensor technology – OFIS - combine to identify various disease states and conditions via proprietary breath biomarkers, volatile organic compounds (VOC’s). DECIPHER is disease agnostic and will speed diagnosis, while improving accuracy over currently available diagnostic methods. The tests use a noninvasive 4-minute breath sample with analysis taking ~15 minutes on our portable, battery powered platform. Initial products include fungal pneumonias, lung cancer (staging, monitoring, differential diagnosis and screening) and C. difficile.
Physical Sciences Inc. (PSI) is an employee-owned company dedicated to inventing, demonstrating, and translating technologies that address critical national needs in defense, security, healthcare, and environmental stewardship. With over 50 years of experience, PSI combines extensive research and development capabilities with a commitment to innovation and customer focus.
The University of Texas at San Antonio (UTSA) is dedicated to the advancement of knowledge through research, teaching, and community engagement. As a premier public research university, UTSA embraces multicultural traditions and serves as a catalyst for socioeconomic development, providing access to educational excellence and preparing citizen leaders for the global environment.
Auburn University Research & Economic Development is dedicated to advancing research and economic growth through a collaborative effort among its various colleges and departments. The organization focuses on fostering innovation, supporting faculty and student research, and facilitating partnerships with industry and government to address societal challenges and enhance the quality of life. Recent initiatives include the launch of the Team Science Series to promote interdisciplinary collaboration and the development of the Gulf Coast Engineering Research Station to address coastal environmental challenges.
Vocxi Health is a diagnostic start-up focused on early disease detection through its innovative MyBreathPrint® system. This noninvasive technology allows for immediate health assessments by analyzing volatile organic compounds (VOCs) in a patient's breath, aiming to revolutionize patient care and improve health outcomes.
Seek Labs is a biotechnology company headquartered in Salt Lake City, Utah, dedicated to advancing scientific discovery and delivering universal healthcare solutions. The company specializes in next-generation point-of-care molecular diagnostics and programmable CRISPR-based therapeutics, aiming to bridge the gap between disease outbreak and intervention. Powered by its proprietary AI discovery engine, BioSeeker™, Seek Labs is building a modular, full-stack system that enables rapid response to emerging pathogens, scalable precision treatments, and accessible diagnostics. The company is committed to global health innovation, sustainability, and community engagement, and is a proud member of Utah's BioHive life sciences ecosystem. Seek Labs' mission is to empower individuals with healthcare solutions tailored to their specific needs, revolutionizing the detection and treatment of diseases for both human and animal health.
The Institute for Integrative & Innovative Research (I3R) at the University of Arkansas is dedicated to pioneering solutions to complex societal challenges through convergence research. With a mission to advance research excellence and stimulate economic development, I3R focuses on deploying innovations at scale through collaboration across various sectors, including academia, industry, and government.
UTMB is dedicated to supporting research, education, and scholarly endeavors, with a focus on creating the future of healthcare through innovative research and community engagement.
Zeteo Tech is a venture-backed biodefense and medical device company that has developed a revolutionary new class of fieldable biological mass spectrometers. Their technology identifies airborne microbes, proteins, and lipids, enabling rapid screening for infectious diseases and bio-threats. With a focus on cost-effective solutions, Zeteo Tech aims to enhance biodefense capabilities and improve patient screening for diseases like tuberculosis.
The University of Queensland (UQ) is one of Australia's leading research and teaching institutions, dedicated to transforming lives through education and research. UQ aims to create a better future by equipping students with the skills and knowledge necessary for their chosen careers, while also addressing some of the world's most complex challenges through innovative research.
The University of Chicago is a prestigious urban research university committed to rigorous inquiry and intellectual freedom. Founded in 1890, it has produced numerous Nobel laureates and is known for its transformative education and groundbreaking research across various fields. The university fosters an inclusive and diverse learning environment, encouraging participation from all community members.
Boston University is a major research institution committed to leading breakthroughs across various disciplines. The Office of Research supports and advances research excellence, fostering collaboration among researchers, industry partners, and government leaders to address significant societal challenges.
Scanogen is a molecular diagnostic company focused on developing rapid and ultra-sensitive detection systems for biomolecules in body fluids. Utilizing their proprietary Single MOLecule Tethering (SMOLT) technology, Scanogen aims to improve healthcare by providing quick and actionable diagnostic results, particularly in the areas of bloodstream and respiratory infections.
Arizona State University
ASU Crosscutting Technologies to Enhance Military Medical Readiness and Resilience
Dr. Rachel Cassalia leads MTEC-supported efforts at ASU to shift military health from reactive care to proactive readiness through data-driven prevention.
University of Pittsburgh
Topical Metformin Lotion for Tendinopathy Prevention
University of Pittsburgh study shows topical metformin prevents overuse tendon injury. This work was sponsored through MTEC project 22-02-MPAI-014.
Theradaptive
Theradaptive’s RESTORE Trial Initiation for OsteoAdapt™ DE
Theradaptive launches RESTORE Phase I/II trial of OsteoAdapt™ DE for faster, precision bone healing in craniofacial injuries. MTEC-funded study targets improved recovery for military and civilian patients.
Altec
Autonomous Rehabilitation Device for Improved Recovery in Warfighters
The OSCIR platform—developed by Altec Inc in collaboration with the Naval Health Research Center—is bringing clinical-grade, real-time movement analysis to the front lines. Funded under MTEC-22-02-MPAI